Fremanezumab  (Synonyms: TEV-48125; LBR-101; PF-04427429; RN-307)

Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine^[1][2][3].

CALCA/CGRP

Fremanezumab (10 μM, 6 h) counteracts the concentration-dependent inhibitory effects of mouse CGRP on LPS (HY-D1056)-induced increases in IL1β, IL6, and IL12 transcripts in primary cultures of C57Bl mouse microglia, but does not alter microglia activation alone upon LPS incubation^[1].
Fremanezumab (72 h) prevents the concentration-dependent inhibition of proliferation of splenocytes derived from day 30 MOG_35-55-immunized NOD by mouse CGRP, but does not alter lymphocyte proliferation alone^[1].
Fremanezumab (1-100 ng, 1 h) reduces immunodetection of human and mouse CGRP with IC₅₀s of 7.94 nM and 19.6 nM, respectively^[1].
Fremanezumab ((0.00001-1 μM) significantly inhibits the vasodilatory effects induced by human αCGRP, rat αCGRP and the metabolically stable CGRP analog SAX in rat cerebral basilar artery segments and reduces the potency of CGRP (pEC₅₀ from 8.0 to 6.3) and SAX (pEC₅₀ from 7.2 to 6.2)^[2]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fremanezumab (100 mg/kg, s.c., once every 2 weeks) shows no impact on disease evolution, survival, spinal cord neurodegeneration, or innate/adaptive immune responses in NOD mice^[1].
Fremanezumab (30 mg/kg, i.v., once) selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in anesthetized male rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145.5 kDa

1655501-53-3

Liquid

Colorless to light yellow

[Fremanezumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Flow cytometric analysis of 1X10⁶ A549 cells with Fremanezumab (HY-P99019, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Pistolesi A, et al. The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis. Eur J Pharmacol. 2025 May 15;995:177415.  [Content Brief]

  [2]. Grell AS, et al. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. Eur J Pharmacol. 2019 Dec 1;864:172726.  [Content Brief]

  [3]. Melo-Carrillo A, et al. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci. 2017 Nov 1;37(44):10587-10596.  [Content Brief]